CRISPR/Cas9-based gene therapy (CRISPR Therapeutics/Vertex Pharmaceuticals)

N/A

Report date: 2025/01/26 18:07:55

Base Information

Drug NameCRISPR/Cas9-based gene therapy (CRISPR Therapeutics/Vertex Pharmaceuticals)
Drug Alias NameN/A
ClassificationBiologics
Mechanisms of ActionCystic fibrosis transmembrane conductance regulator stimulants
TargetsCystic fibrosis transmembrane conductance regulator
Therapy Area/IndicationsCystic Fibrosis
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited StatesSwitzerland
CombinationsNo
Global Highest StatusPreclinical
Highest Status in ChinaN/A
Originator CompaniesCrispr Therapeutics Ag
China Registration ClassN/A

Develop Information

Inactive CompaniesN/A
Active IndicationsCystic Fibrosis
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A